stereotactic ablative radiotherapy

  •   George Lundberg, MD

    This scientific manuscript from Cureus reports results from a Toronto cancer center suggesting that stereotactic radiotherapy offers another option for palliative treatment of inoperable pancreatic cancer.




    “Stereotactic ablative radiotherapy (SABR) yielded a surprisingly low pathologic complete response (pCR) rate in a phase II trial of operable, early-stage lung cancer patients, raising questions about SABR alone in this setting.

    “In the first study to examine neoadjuvant SABR prior to surgery in non-small cell lung cancer (NSCLC), SABR yielded a 60% pCR rate at 10 weeks post-radiation (95% CI 44%-76%), a rate far lower than hypothesized when the trial was designed, reported David Palma, MD, PhD, of the London Health Sciences Centre in London, Ontario, Canada, and colleagues, in JAMA Oncology.”

    Go to full article published by MedPage Today on Feb 22, 2019.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.